Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases.
Brain metastases
Breast Graded Prognosis Assessment
Breast cancer
Prognosis
Survival outcomes
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
20
01
2021
accepted:
19
02
2021
pubmed:
12
3
2021
medline:
15
12
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
Brain metastases (BM) occur in 15-35% of patients with metastatic breast cancer, conferring poor prognosis and impairing quality of life. Clinical scores have been developed to classify patients according to their prognosis. We aimed to check the utility of the Breast Graded Prognostic Assessment (B-GPA) and its modified version (mB-GPA) and compare them in routine clinical practice. This is an ambispective study including all patients with breast cancer BM treated in a single cancer comprehensive center. We analyzed the overall survival (OS) from BM diagnosis until death. The Kaplan-Meier method and Cox proportional hazard regression model were used in the analyses. ROC curves were performed to compare both scores. We included 169 patients; median age was 50 years. HER2-positive and triple negative patients were 33.7% and 20.7%, respectively. At the last follow-up, 90% of the patients had died. Median OS was 12 months (95% confidence interval 8.0-16.0 months). OS was worse in patients with > 3 BM and in patients with triple negative subtype. In our series, we confirm that B-GPA and mB-GPA scores correlated with prognosis. ROC curves showed that B-GPA and mB-GPA have similar prognostic capabilities, slightly in favor of mB-GPA.
Identifiants
pubmed: 33704689
doi: 10.1007/s12094-021-02577-x
pii: 10.1007/s12094-021-02577-x
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Comparative Study
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1761-1768Informations de copyright
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).
Références
Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48:384–94.
pubmed: 7237407
doi: 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8
Fokstuen T, Wilking N, Rutqvist LE, et al. Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat. 2000;62:211–6.
pubmed: 11072785
doi: 10.1023/A:1006486423827
Griguolo G, Jacot W, Kantelhardt E, et al. External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: a multicentric European experience. Breast. 2018;37:36–41.
pubmed: 29073498
doi: 10.1016/j.breast.2017.10.006
pmcid: 29073498
Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25.
pubmed: 22203767
doi: 10.1200/JCO.2011.38.0527
Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol. 2015;33:2239–45.
pubmed: 25987700
pmcid: 5098846
doi: 10.1200/JCO.2014.58.8517
Martin AM, Cagney DN, Catalano PJ, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3:1069–77.
pubmed: 5824221
pmcid: 5824221
doi: 10.1001/jamaoncol.2017.0001
Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113:2638–45.
pubmed: 18833576
doi: 10.1002/cncr.23930
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
pubmed: 16236737
doi: 10.1056/NEJMoa052306
Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–18.
pubmed: 24298071
pmcid: 7580496
doi: 10.1158/1078-0432.CCR-13-0790
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2—positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–52.
pubmed: 25332249
pmcid: 4226805
doi: 10.1200/JCO.2014.55.5730
Kast K, Schoffer O, Link T, et al. Trastuzumab and survival of patients with metastatic breast cancer. Arch Gynecol Obstet. 2017;296:303–12.
pubmed: 28616827
doi: 10.1007/s00404-017-4421-x
Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;19(11):1758835919833519.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2019;382(7):597–609.
pubmed: 31825569
doi: 10.1056/NEJMoa1914609
Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5.
pubmed: 30655533
pmcid: 30655533
doi: 10.1038/s41572-018-0055-y
Moja L, Brambilla C, Compagnoni A, Pistotti V. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2006;2012(4):C006243.
Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004–14.
pubmed: 27604504
pmcid: 27604504
doi: 10.1016/S0140-6736(16)30825-X
Trovo M, Furlan C, Polesel J, et al. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126:177–80.
pubmed: 28943046
doi: 10.1016/j.radonc.2017.08.032
Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma: feasibility and outcome of a local treatment concept. Cancer. 2004;100:1705–11.
pubmed: 15073860
doi: 10.1002/cncr.20167
Huang Z, Sun B, Shen G, et al. Brain metastasis reirradiation in patients with advanced breast cancer. J Radiat Res. 2017;58:142–8.
pubmed: 27707842
pmcid: 5321192
doi: 10.1093/jrr/rrw087
Yomo S, Hayashi M. The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases. J Neurooncol. 2013;113:459–65.
pubmed: 23661101
doi: 10.1007/s11060-013-1138-y
Soon YY, Tham IWK, Lim KH, et al. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev. 2014;2014(3):CD09454.
Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942–8.
pubmed: 19840953
doi: 10.1093/annonc/mdp407
Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–4.
pubmed: 17931798
doi: 10.1016/j.ijrobp.2007.06.074
pmcid: 17931798
Griguolo G, Dieci MV, Giarratano T, et al. Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. J Neurooncol. 2017;131:369–76.
pubmed: 27853958
doi: 10.1007/s11060-016-2309-4
pmcid: 27853958
Sperduto PW, Mesko S, Li J, et al. Beyond an updated graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 2020;107(2):334–43.
pubmed: 32084525
pmcid: 7276246
doi: 10.1016/j.ijrobp.2020.01.051
Sperduto PW, Kased N, Roberge D, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82:2111–7.
pubmed: 21497451
doi: 10.1016/j.ijrobp.2011.02.027
pmcid: 21497451
Laakmann E, Riecke K, Goy Y, et al. Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain. J Cancer Res Clin Oncol. 2016;142:325–32.
pubmed: 26424693
doi: 10.1007/s00432-015-2049-4
pmcid: 26424693
Tai CH, Wu CC, Hwang ME, et al. Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. CNS Oncol. 2018;7:25–34.
pubmed: 29392968
pmcid: 6001561
doi: 10.2217/cns-2017-0023
Zhuang Q, Wong RX, Lian WX, et al. Validation of modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor. Ann Palliat Med. 2019;8:390–400.
pubmed: 30943738
doi: 10.21037/apm.2019.02.05
Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.
doi: 10.1056/NEJMoa1607303
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.
doi: 10.1200/JCO.2017.75.6155
Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):123.
pubmed: 30340505
pmcid: 6194611
doi: 10.1186/s13058-018-1050-7
Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.
pubmed: 30345905
doi: 10.1056/NEJMoa1810527
Gianni L, Dafni U, Gelber RD, et al. HERA 4-year follow-up. Lancet Oncol. 2011;12:236–44.
pubmed: 21354370
doi: 10.1016/S1470-2045(11)70033-X
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205.
pubmed: 28215665
pmcid: 5465633
doi: 10.1016/S0140-6736(16)32616-2
Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–35.
pubmed: 26253814
doi: 10.1016/j.breast.2015.07.008
Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.
doi: 10.1056/NEJMoa1814017
Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer. 2017;84:141–8.
pubmed: 28810186
doi: 10.1016/j.ejca.2017.07.024
Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64–71.
pubmed: 23122784
pmcid: 23122784
doi: 10.1016/S1470-2045(12)70432-1
Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–9.
pubmed: 32468955
doi: 10.1200/JCO.20.00775
Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) †. Immune-related Pathol Response Criteria. 2018;29:1634–57.